J Respir Med Lung Dis | Volume 3, Issue 1 | Research Article | Open Access

Evaluating Clinical Effectiveness of 13-Valent and 23-Valent Pneumococcal Vaccination among People Over 50 Years in Catalonia: The EPIVAC Cohort Study

Angel Vila-Corcoles^* and Olga Ochoa-Gondar

Department of Primary Care, Institute of Catala de la Salut, Spain

^*Correspondance to: Angel Vila-Corcoles 

Fulltext PDF

Abstract

Pneumococcal disease is a major cause of morbidity and mortality worldwide. At present, two anti-pneumococcal vaccines are available for use in adults: the “classical” 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) and the “new” 13-valent Protein-Polysaccharide Conjugate Vaccine (PCV13). This paper describes rationale and design of the EPIVAC (Effectiveness of Pneumococcal and Influenza Vaccinations among Adults in Catalonia) Study, a population-based prospective cohort study with the major aim of evaluating possible clinical benefits from PPsV23 and PCV13 vaccinations in the general adult population over 50 years.

Citation:

Vila-Corcoles A, Ochoa-Gondar O. Evaluating Clinical Effectiveness of 13-Valent and 23-Valent Pneumococcal Vaccination among People Over 50 Years in Catalonia: The EPIVAC Cohort Study. J Respir Med Lung Dis. 2018; 3(1): 1032.